Mass General Brigham researchers found that the intensive cholesterol-lowering therapy evolocumab reduced the risk of a first major cardiovascular event in high-risk patients who did not have known ...
MedPage Today on MSN
PCSK9 Drug Prevents First Heart Events in Diabetes Patients Without Atherosclerosis
VESALIUS-CV further extends PCSK9 inhibitor's primary prevention benefits ...
In high-risk patients with diabetes but without known atherosclerosis, evolocumab reduced risk for a first major CV event compared with placebo, according to a subgroup analysis of the VESALIUS-CV ...
Earlier use of cholesterol lowring drug evolocumab may reduce heart attack and stroke risk in high-risk diabetes patients without known heart disease.
Q4 2025 Earnings Call March 24, 2026 4:30 PM EDTCompany ParticipantsMiranda Benvenuti - Investor Relations ExecutivePeter Altman ...
BioCardia, Inc. (NASDAQ:BCDA) Q4 2025 Earnings Call Transcript March 24, 2026 BioCardia, Inc. beats earnings expectations.
Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported late breaking echocardiography results from its Phase ...
Performed with favorable safety, the diagnostic yield for coronary function testing in patients with ischemia but nonobstructive arteries was found to exceed 90%.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results